Embecta (NASDAQ:EMBC) Stock Breaks Above Two Hundred Day Moving Average – Should You Sell?

Shares of Embecta Corp. (NASDAQ:EMBC) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $6.37 and traded as high as $6.79. Embecta shares last traded at $6.52, with a volume of 1,153,748 shares.

Wall Street Analysts Forecast Growth

EMBC has been the topic of a number of recent analyst reports. Zacks Research raised Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th. Weiss Ratings upgraded shares of Embecta from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $11.00.

Embecta Price Performance

The stock has a market cap of $369.42 million, a price-to-earnings ratio of 4.41 and a beta of 0.81. The firm has a 50 day simple moving average of $5.81 and a two-hundred day simple moving average of $6.37.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Friday, August 7th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.29. The firm had revenue of $271.70 million during the quarter, compared to analysts’ expectations of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The business’s revenue for the quarter was down 8.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, sell-side analysts expect that Embecta Corp. will post 1.84 earnings per share for the current fiscal year.

Insider Activity at Embecta

In other Embecta news, CEO Devdatt Kurdikar purchased 30,000 shares of the stock in a transaction on Wednesday, August 12th. The shares were purchased at an average cost of $4.70 per share, for a total transaction of $141,000.00. Following the purchase, the chief executive officer owned 804,919 shares of the company’s stock, valued at approximately $3,783,119.30. This represents a 3.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Milton Mayo Morris sold 6,293 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $5.88, for a total value of $37,002.84. Following the completion of the transaction, the director owned 53,828 shares of the company’s stock, valued at $316,508.64. The trade was a 10.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have purchased 70,000 shares of company stock worth $334,200 over the last ninety days. 1.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Embecta

Large investors have recently made changes to their positions in the stock. Walleye Capital LLC acquired a new stake in Embecta in the first quarter valued at $7,013,000. Krensavage Asset Management LLC raised its stake in Embecta by 54.4% in the second quarter. Krensavage Asset Management LLC now owns 1,135,340 shares of the company’s stock valued at $3,701,000 after buying an additional 400,000 shares during the period. Chicago Partners Investment Group LLC acquired a new stake in shares of Embecta in the third quarter valued at approximately $1,813,000. Hsbc Holdings PLC lifted its position in shares of Embecta by 1,268.6% in the first quarter. Hsbc Holdings PLC now owns 212,491 shares of the company’s stock valued at $1,882,000 after buying an additional 196,965 shares during the last quarter. Finally, CWA Asset Management Group LLC lifted its position in shares of Embecta by 43.4% in the third quarter. CWA Asset Management Group LLC now owns 537,838 shares of the company’s stock valued at $3,044,000 after buying an additional 162,891 shares during the last quarter. Institutional investors and hedge funds own 93.83% of the company’s stock.

About Embecta

Embecta Corp. (NASDAQ: EMBC) is a global diabetes-care company that develops, manufactures and sells products used to administer insulin and monitor blood glucose. Its portfolio includes pen needles, insulin syringes, safety needles and syringes, lancets, and other diabetes-management products designed for people with diabetes and the health care professionals who support them.

The company also offers digital and connected solutions intended to support diabetes management and improve the delivery of care.